Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8 publications
Multiparametric MRI as a Predictor of PSA Response in Patients Undergoing Stereotactic Body Radiation Therapy for Prostate Cancer.
Journal: Advances in radiation oncology
Published: April 30, 2023
Dosimetric feasibility of neurovascular bundle-sparing stereotactic body radiotherapy with periprostatic hydrogel spacer for localized prostate cancer to preserve erectile function.
Journal: The British journal of radiology
Published: February 15, 2021
Stereotactic body radiotherapy with periprostatic hydrogel spacer for localized prostate cancer: toxicity profile and early oncologic outcomes.
Journal: Radiation oncology (London, England)
Published: March 24, 2019
Velocity-based Adaptive Registration and Fusion for Fractionated Stereotactic Radiosurgery Using the Small Animal Radiation Research Platform.
Journal: International journal of radiation oncology, biology, physics
Published: December 30, 2017
CDKN2A/p16 Loss Implicates CDK4 as a Therapeutic Target in Imatinib-Resistant Dermatofibrosarcoma Protuberans.
Journal: Molecular cancer therapeutics
Published: September 16, 2014
Genome-wide functional screening identifies CDC37 as a crucial HSP90-cofactor for KIT oncogenic expression in gastrointestinal stromal tumors.
Journal: Oncogene
Published: October 10, 2012
The HSP90 inhibitor, AT13387, is effective against imatinib-sensitive and -resistant gastrointestinal stromal tumor models.
Journal: Molecular cancer therapeutics
Published: June 21, 2012
14-3-3 fusion oncogenes in high-grade endometrial stromal sarcoma.
Journal: Proceedings of the National Academy of Sciences of the United States of America
Published: January 07, 2012
Showing 1-8 of 8
Last Updated: 09/26/2026